Group 1 - The market experienced fluctuations on May 26, with the ChiNext index leading the decline, particularly in the innovative drug sector, where the Tianhong Innovative Drug ETF (517380) fell by 1.64% after a drop of over 2.6% earlier in the day [1] - The Tianhong Innovative Drug ETF, launched in 2021, tracks the "Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50" index, providing comprehensive coverage of the innovative drug industry across A-shares and Hong Kong stocks [1] - As of May 23, the Tianhong ETF had a scale of 393 million yuan, making it the largest among five AH innovative drug ETFs in the market [1] Group 2 - Xiangcai Securities predicts that by 2025, the domestic innovative drug industry is expected to reach a turning point, shifting from capital-driven growth to profit-driven growth, which may present opportunities for both performance and valuation recovery in the sector [2]
同标的指数唯一产品，创新药ETF天弘（517380）尾盘拉升，跌幅收窄至1.6%，机构：短期继续看好医药
2 1 Shi Ji Jing Ji Bao Dao·2025-05-26 09:33